<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039412</url>
  </required_header>
  <id_info>
    <org_study_id>ZU-IRB#5089</org_study_id>
    <nct_id>NCT04039412</nct_id>
  </id_info>
  <brief_title>Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt</brief_title>
  <official_title>Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ayman Magd Eldin Mohammad Sadek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zagazig University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall prevalence of H. Pylori in the developing countries is 50.8%, with the highest
      one presented in Africa (79.1%). Hybrid therapy is supposed to be more effective as a
      first-line regimen for Helicobacter pylori infection in Egypt than the Reverse hybrid and
      non-bismuth Levofloxacin quadruple therapies. We are aiming here to compare the Hybrid,
      Reverse hybrid, and Levofloxacin quadruple therapies as first-line therapy, trying to reach
      the safest, cost-effective, and compliance-inducing regimen in Egypt. We will conduct a
      randomized controlled (interventional) study at Zagazig University Hospital, internal
      medicine department clinic, on 330 patients. 110 patients will be allocated to each regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Although the decreasing prevalence of Helicobacter Pylori (H. Pylori) worldwide, it remains
      high in developing countries. According to the most recent studies, the overall prevalence of
      H. Pylori in the developing countries is 50.8%, with the highest one presented in Africa
      (79.1%).

      Unfortunately, the data on the prevalence of H. Pylori, are not available from all the
      countries of Africa. There is a paucity of information about the magnitude of the problem in
      Egypt, according to the few available studies, the prevalence is ranging from 71.7-91.7%.

      The importance of H. Pylori infection lies in the major role in chronic gastritis, gastric
      ulcer, and duodenal ulcer, up to gastric adenocarcinoma, and gastric mucosa-associated
      lymphoid tissue lymphoma.

      Diagnosis of H. Pylori can be through invasive tests, which are cumbersome and expensive
      despite their high sensitivity and specificity. On the contrary, there are more easily and
      cheaper non-invasive tests, especially H. Pylori stool antigen and urea breath test that has
      a higher sensitivity than serology.

      The decreasing eradication rate of the standard triple therapy (STT) below 80% due to the
      emergence of resistant strains to Clarithromycin, raise the need for newer therapies that
      provide higher efficacy, and in the same time, better safety and compliance.

      Bismuth-containing quadruple therapy came as the treatment of choice that avoids
      Clarithromycin use, but it was a non-reasonable option for the countries that are lacking in
      bismuth salts and/or tetracycline, beside of the complex administration and low safety. It
      raises the era of the competing sequential and concomitant non-bismuth (clarithromycin
      containing) quadruple treatments.

      A novel two-step (dual-quadruple) treatment called the hybrid therapy (HT), which is actually
      a combined sequential and concomitant therapy, with a lower cost and better efficacy.

      However, the adding of two drugs in the last seven days of the therapy may confuse the
      patient, making him less willing to complete the treatment that promote the idea of reversing
      the sequence (quadruple-dual) in what is called the reverse hybrid therapy (RHT), to simplify
      the treatment in one-step two-phase treatment.

      Another non-Clarithromycin non-Bismuth quadruple therapy that is less complex and safer than
      bismuth quadruple therapy, which is called Levofloxacin quadruple therapy that contains
      levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOND), showed promising results on
      the level of the cure rate and low drug resistance profile.

      Methods:

      Technical Design:

      A) The site of study:

      The study was conducted in Internal medicine department clinic in Zagazig University
      Hospitals.

      B) Sample size:

      Assuming that the eradication rate in patients receiving Hybrid therapy is 91% versus 78.3%
      in Reverse Hybrid therapy. So, the sample size is 309, using OPEN EPI at power 80% and C.I
      95%.

      Tools of data collection:

        1. Medical history to all participants.

        2. Complete clinical examination.

        3. The fecal antigen test (FAT) which identifies H. pylori antigen in the stool by enzyme
           immunoassay was positive in all participants.

      Operational design:

      A) This is a randomized (interventional) study conducted at Zagazig University Hospital,
      internal medicine department clinic after informed consent. All the participants were
      positive for H. pylori fecal antigen test.

      B) Steps of performance: (330) participants were chosen from the Internal Medicine Department
      clinic, grouped into 3 groups:

        1. Group 1: (110) participants received reverse hybrid regimen in the form of
           clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole
           500 mg tid for 1 week, followed by omeprazole 20 mg bid, and amoxicillin 1gm bid in the
           2nd week.

        2. Group2: (110) participants received hybrid regimen in the form of omeprazole 20 mg bid,
           and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20 mg
           bid, amoxicillin 1gm bid, and metronidazole 500 mg tid in the 2nd week.

        3. Group3: (110) participants received Levofloxacin quadruple regimen (LOAD) in the form of
           nitazoxanide 500 mg bid, levofloxacin 250 mg QD, omeprazole 40 mg QD, and doxycycline
           100 mg QD for 10 days

      C) Retesting by The fecal antigen test (FAT) after stopping the regimen by at least one month
      and withholding proton pump inhibitors for four weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 22, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized controlled (interventional) study conducted at Zagazig University Hospital, internal medicine department clinic</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Helicobacter Pylori Infection Cure</measure>
    <time_frame>40-44 days</time_frame>
    <description>Measuring the curative rate of each regimen by a fecal antigen test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>10-14 days</time_frame>
    <description>Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Helicobacter Pylori Treatment Completion</measure>
    <time_frame>10-14 days</time_frame>
    <description>Questionnaire to evaluate the compliance with each treatment regimen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>(1) Hybrid regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(2) Reverse hybrid regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(3) Levofloxacin quadruple regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hybrid regimen</intervention_name>
    <description>two-step (dual-quadruple) treatment</description>
    <arm_group_label>(1) Hybrid regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reverse hybrid regimen</intervention_name>
    <description>one-step two-phase (quadruple-dual) treatment</description>
    <arm_group_label>(2) Reverse hybrid regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin quadruple regimen</intervention_name>
    <description>non-Clarithromycin non-Bismuth quadruple therapy</description>
    <arm_group_label>(3) Levofloxacin quadruple regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive Helicobacter pylori antigen in the stool

          -  Treatment-naive

        Exclusion Criteria:

          -  Previous treatment for Helicobacter pylori

          -  Drug hypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman MM Sadek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Zagazig University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Human Medicine, Zagazig University</name>
      <address>
        <city>Zagazig</city>
        <state>Sharkia</state>
        <zip>44519</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Torres J, Pérez-Pérez G, Goodman KJ, Atherton JC, Gold BD, Harris PR, la Garza AM, Guarner J, Muñoz O. A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res. 2000 Sep-Oct;31(5):431-69. Review.</citation>
    <PMID>11179581</PMID>
  </reference>
  <reference>
    <citation>Zamani M, Ebrahimtabar F, Zamani V, Miller WH, Alizadeh-Navaei R, Shokri-Shirvani J, Derakhshan MH. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018 Apr;47(7):868-876. doi: 10.1111/apt.14561. Epub 2018 Feb 12.</citation>
    <PMID>29430669</PMID>
  </reference>
  <reference>
    <citation>Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27. Review.</citation>
    <PMID>28456631</PMID>
  </reference>
  <reference>
    <citation>El Dine SS, Mubarak M, Salama R, El Raziky M, El Sherbiny E, Zakaria S, Zakaria MS. Low Seroprevalence of anti-CagA antibodies inspite of high seroprevalence of anti-H. Pylori antibodies in rural Egyptian community. Research Journal of Medicine and Medical Sciences. 2008; 3(2):118-23.</citation>
  </reference>
  <reference>
    <citation>Diab M, El-Dine SS, Aboul-Fadl L, Shemis M, Omran Z, Badawi A, El-Ghannam M, El-Ray A, Fam N, El-Defrawy I, El-Sherbini E. Helicobacterpylori cag pathogenicity island genes among dyspeptic patients with chronic gastritis. Egypt J Med Microbiol. 2009; 18:43-53.</citation>
  </reference>
  <reference>
    <citation>Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002 Oct 10;347(15):1175-86. Review.</citation>
    <PMID>12374879</PMID>
  </reference>
  <reference>
    <citation>Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014 Feb 14;20(6):1438-49. doi: 10.3748/wjg.v20.i6.1438. Review.</citation>
    <PMID>24587620</PMID>
  </reference>
  <reference>
    <citation>Huang YK, Wu MC, Wang SS, Kuo CH, Lee YC, Chang LL, Wang TH, Chen YH, Wang WM, Wu DC, Kuo FC. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis. 2012 Apr;13(4):232-8. doi: 10.1111/j.1751-2980.2012.00575.x.</citation>
    <PMID>22435509</PMID>
  </reference>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084.</citation>
    <PMID>22491499</PMID>
  </reference>
  <reference>
    <citation>Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori Eradication Therapies in the Era of Increasing Antibiotic Resistance: A Paradigm Shift to Improved Efficacy. Gastroenterol Res Pract. 2012;2012:757926. doi: 10.1155/2012/757926. Epub 2012 Jun 19.</citation>
    <PMID>22778723</PMID>
  </reference>
  <reference>
    <citation>Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.</citation>
    <PMID>27769562</PMID>
  </reference>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.</citation>
    <PMID>27707777</PMID>
  </reference>
  <reference>
    <citation>Liatsos C, Georgopoulos SD. Helicobacter pylori best treatment approach: should a national consensus be the best consensus? Ann Gastroenterol. 2017;30(6):704-706. doi: 10.20524/aog.2017.0183. Epub 2017 Aug 2.</citation>
    <PMID>29118570</PMID>
  </reference>
  <reference>
    <citation>Hsu PI, Tsay FW, Graham DY, Tsai TJ, Tsai KW, Kao JY, Peng NJ, Kuo CH, Kao SS, Wang HM, Lin TF, Wu DC; Taiwan Acid-related Disease (TARD) Study Group. Equivalent Efficacies of Reverse Hybrid and Bismuth Quadruple Therapies in Eradication of Helicobacter pylori Infection in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2018 Sep;16(9):1427-1433. doi: 10.1016/j.cgh.2018.03.031. Epub 2018 Mar 31.</citation>
    <PMID>29609070</PMID>
  </reference>
  <reference>
    <citation>Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol. 2011 Nov;106(11):1970-5. doi: 10.1038/ajg.2011.306. Epub 2011 Oct 11.</citation>
    <PMID>21989146</PMID>
  </reference>
  <reference>
    <citation>Abd-Elsalam S, Kobtan A, El-Kalla F, Elkhalawany W, Nawasany SE, Saif SA, Yousef M, Ali LA, Soliman S, Mansour L, Habba E, Soliman H, Rizk F, Shehata MA. A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience. Medicine (Baltimore). 2016 Jun;95(24):e3879. doi: 10.1097/MD.0000000000003879. Erratum in: Medicine (Baltimore). 2016 Aug 07;95(31):e5074.</citation>
    <PMID>27310977</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <results_first_submitted>September 22, 2019</results_first_submitted>
  <results_first_submitted_qc>November 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 26, 2019</results_first_posted>
  <last_update_submitted>November 23, 2019</last_update_submitted>
  <last_update_submitted_qc>November 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Zagazig University</investigator_affiliation>
    <investigator_full_name>Ayman Magd Eldin Mohammad Sadek</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Helicobacter Pylori Infection</keyword>
  <keyword>Quadruple Therapy</keyword>
  <keyword>Egypt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>After study publication</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT04039412/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We conducted an interventional randomized trial at the internal medicine department clinic, Zagazig University Hospital, Zagazig, Egypt, in the period from July 2018 to June 2019. We allocated the participants attending the clinic by simple randomization over the three treatment groups.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>(1) Reverse Hybrid Regimen</title>
          <description>clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
Reverse hybrid regimen: one-step two-phase (quadruple-dual) treatment</description>
        </group>
        <group group_id="P2">
          <title>(2) Hybrid Regimen</title>
          <description>omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
Hybrid regimen: two-step (dual-quadruple) treatment</description>
        </group>
        <group group_id="P3">
          <title>(3) Levofloxacin Quadruple Regimen</title>
          <description>levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
Levofloxacin quadruple regimen: non-Clarithromycin non-Bismuth quadruple therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>(1) Reverse Hybrid Regimen</title>
          <description>clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20mg bid, and amoxicillin 1gm bid in the 2nd week.
Reverse hybrid regimen: one-step two-phase (quadruple-dual) treatment</description>
        </group>
        <group group_id="B2">
          <title>(2) Hybrid Regimen</title>
          <description>omeprazole 20mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week.
Hybrid regimen: two-step (dual-quadruple) treatment</description>
        </group>
        <group group_id="B3">
          <title>(3) Levofloxacin Quadruple Regimen</title>
          <description>levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days. (LOAD)
Levofloxacin quadruple regimen: non-Clarithromycin non-Bismuth quadruple therapy</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="110"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="110"/>
                    <count group_id="B4" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.05" spread="9.772"/>
                    <measurement group_id="B2" value="32.31" spread="9.409"/>
                    <measurement group_id="B3" value="32.44" spread="9.713"/>
                    <measurement group_id="B4" value="32.27" spread="9.604"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="110"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="110"/>
                    <count group_id="B4" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Egypt</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="110"/>
                    <count group_id="B2" value="110"/>
                    <count group_id="B3" value="110"/>
                    <count group_id="B4" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Helicobacter Pylori Infection Cure</title>
        <description>Measuring the curative rate of each regimen by a fecal antigen test</description>
        <time_frame>40-44 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>(1) Reverse Hybrid Regimen</title>
            <description>clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20 mg bid, and amoxicillin 1gm bid in the 2nd week</description>
          </group>
          <group group_id="O2">
            <title>(2) Hybrid Regimen</title>
            <description>omeprazole 20 mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week</description>
          </group>
          <group group_id="O3">
            <title>(3) Levofloxacin Quadruple Regimen</title>
            <description>levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Helicobacter Pylori Infection Cure</title>
          <description>Measuring the curative rate of each regimen by a fecal antigen test</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-Emergent Adverse Events</title>
        <description>Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events</description>
        <time_frame>10-14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>(1) Reverse Hybrid Regimen</title>
            <description>clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20 mg bid, and amoxicillin 1gm bid in the 2nd week</description>
          </group>
          <group group_id="O2">
            <title>(2) Hybrid Regimen</title>
            <description>omeprazole 20 mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week</description>
          </group>
          <group group_id="O3">
            <title>(3) Levofloxacin Quadruple Regimen</title>
            <description>levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events</title>
          <description>Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Helicobacter Pylori Treatment Completion</title>
        <description>Questionnaire to evaluate the compliance with each treatment regimen</description>
        <time_frame>10-14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>(1) Reverse Hybrid Regimen</title>
            <description>109 participants in per-protocol analysis (99.1%)</description>
          </group>
          <group group_id="O2">
            <title>(2) Hybrid Regimen</title>
            <description>107 participants in per-protocol analysis (97.3%)</description>
          </group>
          <group group_id="O3">
            <title>(3) Levofloxacin Quadruple Regimen</title>
            <description>108 participants in per-protocol analysis (98.2%)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Helicobacter Pylori Treatment Completion</title>
          <description>Questionnaire to evaluate the compliance with each treatment regimen</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>We followed up the occurrence of adverse events after one week of therapy, at the end of treatment, and Up to 45 days.</time_frame>
      <desc>We divided the severity of adverse event according to the extent of daily activities limitation, into mild, moderate, and severe (no limitation, partial limitation, and profound limitation respectively).</desc>
      <group_list>
        <group group_id="E1">
          <title>(1) Reverse Hybrid Regimen</title>
          <description>clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid for 1 week, followed by omeprazole 20 mg bid, and amoxicillin 1gm bid in the 2nd week</description>
        </group>
        <group group_id="E2">
          <title>(2) Hybrid Regimen</title>
          <description>omeprazole 20 mg bid, and amoxicillin 1gm bid in the 1st week, then clarithromycin 500mg bid, omeprazole 20 mg bid, amoxicillin 1gm bid, and metronidazole 500mg tid in the 2nd week</description>
        </group>
        <group group_id="E3">
          <title>(3) Levofloxacin Quadruple Regimen</title>
          <description>levofloxacin 250mg QD, omeprazole 40mg QD, nitazoxanide 500mg bid, and doxycycline 100mg QD for 10 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="110"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="110"/>
                <counts group_id="E3" events="37" subjects_affected="37" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General symptoms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="110"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ayman Fathy Elsayed</name_or_title>
      <organization>Zagazig University-Faculty of Human Medicine</organization>
      <phone>+201125020593</phone>
      <email>aymanf28@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

